SG11201609993YA - Treatment of immune disorders - Google Patents

Treatment of immune disorders

Info

Publication number
SG11201609993YA
SG11201609993YA SG11201609993YA SG11201609993YA SG11201609993YA SG 11201609993Y A SG11201609993Y A SG 11201609993YA SG 11201609993Y A SG11201609993Y A SG 11201609993YA SG 11201609993Y A SG11201609993Y A SG 11201609993YA SG 11201609993Y A SG11201609993Y A SG 11201609993YA
Authority
SG
Singapore
Prior art keywords
treatment
immune disorders
immune
disorders
Prior art date
Application number
SG11201609993YA
Other languages
English (en)
Inventor
Silviu Itescu
Paul Simmons
Original Assignee
Mesoblast Internat Sàrl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2014902194A external-priority patent/AU2014902194A0/en
Application filed by Mesoblast Internat Sàrl filed Critical Mesoblast Internat Sàrl
Publication of SG11201609993YA publication Critical patent/SG11201609993YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
SG11201609993YA 2014-06-10 2015-06-01 Treatment of immune disorders SG11201609993YA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2014902194A AU2014902194A0 (en) 2014-06-10 Treatment of immune disorders
AU2014902257A AU2014902257A0 (en) 2014-06-13 Treatment of immune disorders 2
PCT/EP2015/062138 WO2015189063A1 (en) 2014-06-10 2015-06-01 Treatment of immune disorders

Publications (1)

Publication Number Publication Date
SG11201609993YA true SG11201609993YA (en) 2016-12-29

Family

ID=53385603

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201609993YA SG11201609993YA (en) 2014-06-10 2015-06-01 Treatment of immune disorders

Country Status (10)

Country Link
US (3) US10624930B2 (ja)
EP (2) EP3154565B1 (ja)
JP (4) JP6800757B2 (ja)
KR (2) KR20230038590A (ja)
CN (2) CN106659743B (ja)
AU (2) AU2015273799B2 (ja)
CA (1) CA2950804C (ja)
HK (1) HK1231386A1 (ja)
SG (1) SG11201609993YA (ja)
WO (1) WO2015189063A1 (ja)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6184942B2 (ja) * 2011-06-03 2017-08-23 メゾブラスト，インコーポレーテッド 神経疾患を治療するまたは予防する方法
KR20230038590A (ko) * 2014-06-10 2023-03-20 메조블라스트 인터내셔널 에스에이알엘 면역 장애의 치료
CN106929474B (zh) * 2017-03-31 2021-09-14 北京恒峰铭成生物科技有限公司 一种m2巨噬细胞诱导剂
EP3600354B1 (en) * 2017-03-31 2023-09-20 Wisconsin Alumni Research Foundation Generation of therapeutic cells using extracellular components of target organs
AU2018375151A1 (en) * 2017-11-29 2020-06-11 Figene, Llc Interaction of fibroblasts and immune cells for activation and uses thereof
CN112007165B (zh) * 2020-08-27 2021-10-08 北京大学人民医院 巨噬细胞极化调节剂及其在促进血小板生成中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
AU2003901668A0 (en) 2003-03-28 2003-05-01 Medvet Science Pty. Ltd. Non-haemopoietic precursor cells
EP2361970A1 (en) * 2004-09-24 2011-08-31 Angioblast Systems Incorporated Method of enhancing proliferation and/or survival of mesenchymal precursor cells (MPC)
KR101617319B1 (ko) 2005-04-12 2016-05-02 메소블라스트, 아이엔씨. 조직 비특이적인 알카리 포스파타제에 의한 다분화성 성체 세포의 분리
KR20110086176A (ko) * 2008-11-19 2011-07-27 안트로제네시스 코포레이션 양막 유래 부착성 세포
JP5678360B2 (ja) * 2009-09-28 2015-03-04 株式会社ジーシー 間葉系幹細胞の培養方法
WO2012051210A2 (en) * 2010-10-11 2012-04-19 The Administrators Of The Tulane Educational Fund Mesenchymal stem cells and related therapies
DK2785359T3 (en) * 2011-11-30 2018-10-29 Astellas Inst For Regenerative Medicine MESENKYMAL STROMACELLES AND APPLICATIONS RELATED
CN102899293A (zh) * 2012-11-01 2013-01-30 上海市肺科医院 促血管生成素1基因修饰的间充质干细胞、及其构建方法与应用
SG10202000644TA (en) * 2014-04-07 2020-03-30 Mesoblast Int Sarl Improved Stem Cell Composition
KR20230038590A (ko) 2014-06-10 2023-03-20 메조블라스트 인터내셔널 에스에이알엘 면역 장애의 치료

Also Published As

Publication number Publication date
JP7279212B2 (ja) 2023-05-22
US20200281984A1 (en) 2020-09-10
WO2015189063A1 (en) 2015-12-17
US10624930B2 (en) 2020-04-21
US11406669B2 (en) 2022-08-09
AU2020244403B2 (en) 2024-03-07
US20230141347A1 (en) 2023-05-11
AU2020244403A1 (en) 2020-10-29
CN106659743B (zh) 2022-03-01
CN114129598A (zh) 2022-03-04
KR20230038590A (ko) 2023-03-20
US20170106023A1 (en) 2017-04-20
JP6800757B2 (ja) 2020-12-16
CA2950804A1 (en) 2015-12-17
AU2015273799A1 (en) 2016-12-15
JP2021028337A (ja) 2021-02-25
CA2950804C (en) 2023-08-22
JP2022040254A (ja) 2022-03-10
EP3154565A1 (en) 2017-04-19
JP2017526619A (ja) 2017-09-14
JP7009594B2 (ja) 2022-02-10
HK1231386A1 (zh) 2017-12-22
EP3154565B1 (en) 2023-05-03
AU2015273799B2 (en) 2020-07-02
KR20170007854A (ko) 2017-01-20
CN106659743A (zh) 2017-05-10
JP2023090901A (ja) 2023-06-29
EP4137146A1 (en) 2023-02-22

Similar Documents

Publication Publication Date Title
IL252839A0 (en) Treatment of boils
IL285151B1 (en) Methods for the treatment of fgf21-related disorders
GB201701673D0 (en) Methods of well treatment
FI3851537T3 (fi) Hyperbilirubinemian hoito
IL285003A (en) Treatment of episode disorders
SG11201609652RA (en) Treatment of polybacterials infections
HK1231386A1 (zh) 免疫疾病的治療
HK1244711A1 (zh) Hmgb1介導的炎症的治療
GB201410116D0 (en) Method of treatment
GB201408387D0 (en) Treatment of respiratory disorders
IL253028A0 (en) treatment method
GB201416832D0 (en) Methods of treatment
GB201412578D0 (en) Treatment of neurological diseases
GB201607388D0 (en) Treatment of impulsivity-related disorders
SG11201702700UA (en) Methods for the treatment of peri-implantitis
GB201412010D0 (en) Treatment of hypertransaminasemia
GB201411027D0 (en) Treatment
GB201512139D0 (en) Methods of treatment
AU2014902194A0 (en) Treatment of immune disorders
GB201602784D0 (en) New treatment of CFTR-related disorders
AU2014902257A0 (en) Treatment of immune disorders 2
PT3851537T (pt) Tratamento da hiperbilirrubinemia
GB201414023D0 (en) Treatment of autoimmune diseases
GB201421982D0 (en) Method of treatment
GB201421980D0 (en) Method of treatment